Tumor Hypoxia on <sup>18</sup>F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma
In this cohort study using pooled analysis of prospective nonrandomized clinical trials incorporating FMISO PET in the definitive management of HNSCC, persistent intratreatment hypoxia was associated with increased risk of DM and worse OS. Conversely, all patients with hypoxia-negative disease before treatment remained free of DM. These findings suggest that pretreatment and intratreatment FMISO PET results may serve as biomarkers for DM risk and aid in identifying candidates for escalated therapeutic strategies.
Authors
- Heiko M. Schöder (ORCID: https://orcid.org/0000-0002-5170-4185)
- Milan Grkovski (ORCID: https://orcid.org/0000-0001-7228-9497)
- Joseph O. Deasy (ORCID: https://orcid.org/0000-0002-9437-266X)
- Nadeem Riaz (ORCID: https://orcid.org/0000-0001-9873-5862)
- John L. Humm (ORCID: https://orcid.org/0000-0003-4245-5591)
- Nancy Y. Lee (ORCID: https://orcid.org/0000-0003-3044-9522)
- Rick Wray (ORCID: https://orcid.org/0000-0002-9192-4334)
- Eric Jeffrey Sherman (ORCID: https://orcid.org/0000-0002-4960-4783)
- Richard J. Wong (ORCID: https://orcid.org/0000-0001-6259-7314)
- Chengcheng Gui (ORCID: https://orcid.org/0000-0003-3053-5973)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.36407
- Citations
- 7
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.00